伴侶動物藥品市場規模、佔有率和成長分析（按產品、動物種類、給藥途徑、通路和地區分類）－2025-2032年產業預測

預計到 2023 年，全球伴侶動物藥品市場規模將達到 159 億美元，到 2024 年將達到 172 億美元，到 2032 年將達到 323.2 億美元，預測期（2025-2032 年）的複合年成長率為 8.2%。

全球伴侶動物藥品市場呈現穩定成長態勢，主要受寵物飼養率上升和寵物健康領域投資增加的推動，而這又主要源自於人們對寵物福利意識的不斷提高。犬貓作為最常見的伴侶動物，抗感染劑、疫苗、疼痛管理藥物和皮膚病治療產品的需求尤其顯著。獸醫診斷和藥物傳輸技術的創新，以及個人化寵物醫療的發展，正在推動市場動態。關節炎、糖尿病和肥胖等慢性疾病發病率的上升，使得長期治療方案的需求日益成長，從而刺激了市場需求。寵物人性化趨勢，尤其是在北美和歐洲，正在促進研發和新產品開發。此外，獸醫遠距醫療和網路藥局服務的擴展，正在改善寵物獲得治療的機會，尤其是在服務不足的地區。同時，由於經濟發展和獸醫保健服務的改善，亞太和拉丁美洲市場正經歷快速成長。

全球伴侶動物藥品市場促進因素

全球伴侶動物藥品市場的主要驅動力是人們對寵物飼養的認知和接受度不斷提高，這推動了對獸醫保健產品和服務的需求。隨著越來越多的家庭將寵物視為家庭成員，人們對寵物的整體健康和福祉也日益關注。這一趨勢的促進因素包括可支配收入的成長、都市化的加快以及人們對高階寵物護理服務的追求，這些因素促使寵物飼主在預防性護理、慢性病管理和專科藥物方面進行投資。此外，獸醫學的進步和寵物保險的日益普及也進一步推動了該市場的成長。

全球伴侶動物藥品市場阻礙因素

全球伴侶動物藥品市場的主要限制因素之一是獸藥核准和商業化過程中嚴格的法規環境。製藥公司在應對複雜的核准流程方面面臨巨大挑戰，該流程要求進行廣泛的臨床試驗和安全性評估，以確保產品對動物和人類的有效性和安全性。這會導致新產品研發成本增加，上市時間延長。此外，區域監管差異也會阻礙公司拓展國際產品線，進一步增加市場進入和成長策略的複雜性。

全球伴侶動物醫藥市場趨勢

隨著寵物越來越被擬人化，全球伴侶動物藥品市場對高品質治療藥物的需求顯著成長。這種轉變推動了對符合人類標準的醫療保健解決方案的需求，包括文明病治療、心理健康護理和疼痛管理。由於寵物飼主越來越重視寵物的健康和福祉，處方藥的需求也大幅增加，其中包括長效注射和抗焦慮藥物。這一趨勢在都市區市場尤其明顯，寵物飼主熱衷於投資先進的醫療保健方案，以提升伴侶動物的生活品質。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2024）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

伴侶動物藥品市場規模（依產品分類）及複合年成長率（2025-2032 年）

• 市場概覽
• 製藥
  • 抗寄生蟲藥物
  • 抗發炎藥
  • 抗感染劑
  • 皮質類固醇
  • 鎮靜劑
  • 循環系統藥物
  • 消化器官系統藥物
• 疫苗
  • 活病毒疫苗）
  • 去活化疫苗
  • 重組疫苗
• 藥用飼料添加劑
  • 抗生素
  • 維他命
  • 胺基酸
  • 酵素
  • 抗氧化劑
  • 益生元和益生菌
  • 礦物
  • 碳水化合物
  • 丙二醇

伴侶動物藥品市場規模（以動物類型分類）及複合年成長率（2025-2032 年）

• 市場概覽
• 狗
• 貓
• 馬
• 其他動物物種

伴侶動物藥品市場規模（依給藥途徑及複合年成長率分類）（2025-2032 年）

• 市場概覽
• 口服
• 注射
• 外用
• 其他給藥途徑

伴侶動物藥品市場規模（依通路分類）及複合年成長率（2025-2032 年）

• 市場概覽
• 獸醫院藥房
• 電子商務
• 零售藥房

伴侶動物藥品市場規模及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2024 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2024 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2022-2024年營收年比比較

主要企業簡介

• Zoetis Inc.（United States）
• Boehringer Ingelheim International GmbH（Germany）
• Merck & Co., Inc.（United States）
• Elanco Animal Health Incorporated（United States）
• IDEXX Laboratories, Inc.（United States）
• Virbac SA（France）
• Ceva Sante Animale SA（France）
• Dechra Pharmaceuticals PLC（United Kingdom）
• Vetoquinol SA（France）
• Phibro Animal Health Corporation（United States）
• Bayer AG（Germany）
• Norbrook Laboratories（United Kingdom）
• Krka, dd, Novo mesto（Slovenia）
• Intas Pharmaceuticals（India）
• Hester Biosciences Ltd.（India）
• Zydus Animal Health（India）
• Abbott Laboratories（United States）
• IDT Biologika（Germany）
• Bimeda（Ireland）
• Neogen Corporation（United States）

結論與建議

Global Companion Animal Pharmaceuticals Market size was valued at USD 15.9 billion in 2023 and is poised to grow from USD 17.2 billion in 2024 to USD 32.32 billion by 2032, growing at a CAGR of 8.2% during the forecast period (2025-2032).

The global companion animal pharmaceuticals market demonstrates consistent growth, propelled by rising pet adoption rates and heightened investment in pet health, largely due to increasing awareness of animal welfare. A surge in demand for anti-infectives, anti-parasitics, vaccines, pain management, and dermatological products is particularly evident for dogs and cats, prominent as companion animals. Innovations in veterinary diagnostics and drug delivery, along with personalized medicine for pets, are enhancing market dynamics. The growing incidence of chronic diseases like arthritis, diabetes, and obesity necessitates long-term therapeutic approaches, thus boosting demand. Trends toward pet humanization, especially in North America and Europe, stimulate R&D and new product formulations. Additionally, the expansion of veterinary telemedicine and e-pharmacy services is enhancing treatment accessibility, particularly in underserved regions, while Asia-Pacific and Latin America experience rapid growth due to economic progress and improved veterinary services.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Companion Animal Pharmaceuticals market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Companion Animal Pharmaceuticals Market Segments Analysis

Global Companion Animal Pharmaceuticals Market is segmented by Product, Animal Type, Route of Administration, Distribution Channel and region. Based on Product, the market is segmented into Drugs, Vaccines and Medicated feed additives. Based on Animal Type, the market is segmented into Dogs, Cats, Horses and Other animal types. Based on Route of Administration, the market is segmented into Oral, Injectable, Topical and Other routes of administration. Based on Distribution Channel, the market is segmented into Veterinary hospital pharmacies, E-commerce and Retail pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Companion Animal Pharmaceuticals Market

A key market driver for the Global Companion Animal Pharmaceuticals Market is the increasing awareness and acceptance of pet ownership, which has led to a growing demand for veterinary healthcare products and services. As more households consider pets as family members, there is a heightened emphasis on their overall health and well-being. This trend is catalyzed by rising disposable incomes, urbanization, and a shift towards premium pet care services, prompting pet owners to invest in preventive care, chronic disease management, and specialty pharmaceuticals. Additionally, advancements in veterinary medicine and an increase in pet insurance coverage further bolster this market's growth.

Restraints in the Global Companion Animal Pharmaceuticals Market

One key market restraint for the global companion animal pharmaceuticals market is the stringent regulatory environment governing the approval and commercialization of veterinary drugs. Pharmaceutical companies face significant challenges in navigating complex approval processes that require extensive clinical trials and safety evaluations to ensure product efficacy and safety for both animals and humans. This can lead to increased development costs and extended timelines for bringing new products to market. Additionally, the variability in regulations across different regions can create barriers for companies looking to expand their product offerings internationally, further complicating market entry and growth strategies.

Market Trends of the Global Companion Animal Pharmaceuticals Market

The Global Companion Animal Pharmaceuticals market is experiencing a notable trend towards premium therapeutics, fueled by the increasing humanization of pets. This shift has led to a heightened demand for healthcare solutions that parallel human standards, encompassing treatments for lifestyle diseases, mental wellness, and pain management. As pet owners prioritize their animals' health and well-being, there is a significant expansion in prescription therapeutics, including long-acting injectables and anti-anxiety medications. This trend is particularly pronounced in urban markets, where pet owners are more likely to invest in advanced healthcare options that promote optimal quality of life for their companions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Companion Animal Pharmaceuticals Market Size by Product & CAGR (2025-2032)

• Market Overview
• Drugs
  • Antiparasitic
  • Anti-inflammatory
  • Anti-infectives
  • Corticosteroids
  • Tranquilizers
  • Cardiovascular drugs
  • Gastrointestinal drugs
• Vaccines
  • Modified live vaccines (MLV)
  • Killed inactivated vaccines
  • Recombinant vaccines
• Medicated feed additives
  • Antibiotics
  • Vitamins
  • Amino acids
  • Enzymes
  • Antioxidants
  • Prebiotics and probiotics
  • Minerals
  • Carbohydrates
  • Propanediol

Global Companion Animal Pharmaceuticals Market Size by Animal Type & CAGR (2025-2032)

• Market Overview
• Dogs
• Cats
• Horses
• Other animal types

Global Companion Animal Pharmaceuticals Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable
• Topical
• Other routes of administration

Global Companion Animal Pharmaceuticals Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Veterinary hospital pharmacies
• E-commerce
• Retail pharmacies

Global Companion Animal Pharmaceuticals Market Size & CAGR (2025-2032)

• North America (Product, Animal Type, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Product, Animal Type, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Animal Type, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Animal Type, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Animal Type, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Zoetis Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health Incorporated (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IDEXX Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Sante Animale S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dechra Pharmaceuticals PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Phibro Animal Health Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Norbrook Laboratories (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Krka, d. d., Novo mesto (Slovenia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hester Biosciences Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Animal Health (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IDT Biologika (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bimeda (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neogen Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations